AU4652100A - Controlled delivery of bisphosphonates - Google Patents

Controlled delivery of bisphosphonates

Info

Publication number
AU4652100A
AU4652100A AU46521/00A AU4652100A AU4652100A AU 4652100 A AU4652100 A AU 4652100A AU 46521/00 A AU46521/00 A AU 46521/00A AU 4652100 A AU4652100 A AU 4652100A AU 4652100 A AU4652100 A AU 4652100A
Authority
AU
Australia
Prior art keywords
bisphosphonates
controlled delivery
delivery
controlled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU46521/00A
Inventor
Petr Kuzma
Agis Kydonieus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HYDROMED SCIENCES A DIVISION OF GP STRATEGIES Corp
Original Assignee
HYDROMED SCIENCES A DIVISION O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HYDROMED SCIENCES A DIVISION O filed Critical HYDROMED SCIENCES A DIVISION O
Publication of AU4652100A publication Critical patent/AU4652100A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU46521/00A 1999-04-22 2000-04-19 Controlled delivery of bisphosphonates Abandoned AU4652100A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13072899P 1999-04-22 1999-04-22
US60130728 1999-04-22
PCT/US2000/010696 WO2000064516A1 (en) 1999-04-22 2000-04-19 Controlled delivery of bisphosphonates

Publications (1)

Publication Number Publication Date
AU4652100A true AU4652100A (en) 2000-11-10

Family

ID=22446043

Family Applications (1)

Application Number Title Priority Date Filing Date
AU46521/00A Abandoned AU4652100A (en) 1999-04-22 2000-04-19 Controlled delivery of bisphosphonates

Country Status (4)

Country Link
EP (1) EP1210138A4 (en)
AU (1) AU4652100A (en)
CA (1) CA2370769A1 (en)
WO (1) WO2000064516A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL125336A0 (en) 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
US7008645B2 (en) 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
US6984400B2 (en) 1998-07-14 2006-01-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of treating restenosis using bisphosphonate nanoparticles
FR2803521B1 (en) * 2000-01-12 2002-10-25 Ceva Sante Animale USE OF TILUDRONIC ACID AND ITS DERIVATIVES IN POULTRY FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR PREVENTING AND TREATING OSTEOPOROSIS
US7829074B2 (en) 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
US20020151876A1 (en) * 2001-02-07 2002-10-17 Tai-Wah Chan Devices and methods for management of bone density
KR20020080018A (en) * 2001-04-10 2002-10-23 한국화학연구원 A controlled/sustained implant delivery containing bisphosphonate
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
FI20031120A0 (en) * 2003-07-31 2003-07-31 Bci Bioabsorbable Concepts Ltd Multifunctional implant device
ES2561463T3 (en) * 2003-08-21 2016-02-26 Addbio Ab Implant device coated with bisphosphonate and method for it
WO2010111627A1 (en) * 2009-03-26 2010-09-30 Psivida Us, Inc. Implantable formulations of bisphosphonic acids
AU2010278860B2 (en) 2009-07-31 2016-05-26 Thar Pharma, Llc Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
WO2011103307A1 (en) * 2010-02-17 2011-08-25 Georgia Tech Research Corporation Compositions and methods for modifying in vivo calcification of hydrogels
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
JO3394B1 (en) 2014-07-04 2019-10-20 Osteo Pharma B V Compositions and products for use in the treatment of bone fractures and defects
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
WO2019232114A1 (en) * 2018-06-01 2019-12-05 The University Of North Carolina At Chapel Hill Injectable thermoresponsive hydrogels as a combinatory modality for controlled drug delivery, biomaterial implant and 3d printing bioink

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753652A (en) * 1984-05-04 1988-06-28 Children's Medical Center Corporation Biomaterial implants which resist calcification
US5196409A (en) * 1989-08-20 1993-03-23 Yissum, Research Development Company Of The Hebrew University Of Jerusalem Bisphosphonates, pharmaceutical compositions, and process for the treatment of irregularities in calcium metabolism
EP0675723A4 (en) * 1992-12-23 1998-08-05 Merck & Co Inc Bisphosphonate/estrogen therapy for treating and preventing bone loss.
FI92465C (en) * 1993-04-14 1994-11-25 Risto Tapani Lehtinen A method for handling endo-osteal materials
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
JP3476930B2 (en) * 1994-11-16 2003-12-10 オリンパス株式会社 Biological implants
AU5973496A (en) * 1995-06-06 1996-12-24 Merck & Co., Inc. Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices
US5898038A (en) * 1996-03-19 1999-04-27 Board Of Regents, The University Of Texas System Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis

Also Published As

Publication number Publication date
WO2000064516A1 (en) 2000-11-02
EP1210138A1 (en) 2002-06-05
EP1210138A4 (en) 2003-05-07
CA2370769A1 (en) 2000-11-02

Similar Documents

Publication Publication Date Title
AU5914999A (en) Controlled release drug delivery
AU4652100A (en) Controlled delivery of bisphosphonates
AU2492000A (en) Implantable neuro-stimulator
AU3342599A (en) Delivery catheter
AU6168699A (en) Non-compliant system for delivery of implant material
AU5588499A (en) Implant delivery assembly
AU4981200A (en) Stent delivery system
AU5259100A (en) Medicament
AU7059300A (en) Immediate provisional implant
AU6956398A (en) Implant delivery system
AU4139801A (en) Controlled delivery of antigens
AU3007801A (en) Medicament dispenser
AU2509901A (en) Medicament dispenser
AU2212300A (en) Delivery vault
AU6109400A (en) Atomizer system
AU3520900A (en) Implantable drug delivery system
AU7003500A (en) Delivery box
AU1514401A (en) Medicament dispenser
AU5092099A (en) Vibroacoustic delivery system
AU1541601A (en) Syringes
AU2000253054A1 (en) Implantable fluid delivery system
AU5003800A (en) Implant system
AU2331100A (en) Ceramic coating
AU5429699A (en) Drug targeting
AU5745900A (en) Suspoemulsion system for delivery of actives

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase